Targeting B cells and antibody in transplantation

American Journal of Transplantation

Volumn 11, Issue 7, 2011, Pages 1359-1367

  Clatworthy, M R ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Alloantibody; antibody mediated rejection; B cells; desensitization; intravenous immunoglobulin; regulatory B cells; rituximab

Indexed keywords

CD19 ANTIBODY; CD20 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; B LYMPHOCYTE; CHRONIC DISEASE; HISTOCOMPATIBILITY COMPLEX; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNE RESPONSE; KIDNEY TRANSPLANTATION; PLASMA CELL; PRIORITY JOURNAL; REVIEW; T CELL DEPLETION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGEN-PRESENTING CELLS; ANTILYMPHOCYTE SERUM; B-LYMPHOCYTES; GRAFT REJECTION; HUMANS; LYMPHOCYTE DEPLETION; TRANSPLANTATION IMMUNOLOGY;

EID: 79959823291     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03554.x     Document Type: Review

References (54)

1. Lund FE, Randall TD, Effector and regulatory B cells: Modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010; 10: 236-247.
2. Noorchashm H, Reed AJ, Rostami SY, et al,. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol 2006; 177: 7715-7722. (Pubitemid 44846287)
3. Ng YH, Oberbarnscheidt MH, Chandramoorthy HC, Hoffman R, Chalasani G,. B cells help alloreactive T cells differentiate into memory T cells. Am J Transplant 2010; 10: 1970-1980.
4. Vinuesa CG, Linterman MA, Goodnow CC, Randall KL,. T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol Rev 2010; 237: 72-89.
5. Thaunat O, Field AC, Dai J, Louedec L, Patey N, Bloch MF, et al,. Lymphoid neogenesis in chronic rejection: Evidence for a local humoral alloimmune response. Proc. Natl Acad Sci U S A 2005; 102: 14723-14728. (Pubitemid 41457123)
6. Kerjaschki D, Regele HM, Moosberger I, et al,. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol 2004; 15: 603-612. (Pubitemid 38294790)
7. Wehner JR, Fox-Talbot K, Halushka MK, et al,. B cells and plasma cells in coronaries of chronically rejected cardiac transplants. Transplantation 2010; 89: 1141-1148.
8. Drayton DL, Liao S, Mounzer RH, Ruddle NH,. Lymphoid organ development: From ontogeny to neogenesis. Nat Immunol 2006; 7: 344-353.
9. Scholz JL, Crowley JE, Tomayko MM, et al,. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc. Natl Acad Sci U S A 2008; 105: 15517-15522.
10. Parsons RF, Vivek K, Redfield RR,. et al. (B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. Transplant Rev 2010; 24: 207-221.
11. Smith KG, Clatworthy MR,. FcgammaRIIB in autoimmunity and infection: Evolutionary and therapeutic implications. Nat Rev Immunol 2010; 10: 328-343.
12. Roopenian DC, Akilesh S,. FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715-725. (Pubitemid 47327396)
13. Jordan SC, Toyoda M, Vo AA,. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009; 88: 1-6.
14. Vaccaro C, Zhou J, Ober RJ, Ward ES,. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005; 23: 1283-1288. (Pubitemid 41486856)
15. Blair PA, Norena LY, Flores-Borja F, et al,. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010; 32: 129-140.
16. Iwata Y, Matsushita T, Horikawa M, et al,. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011; 117: 530-541.
17. DiLillo DJ, Matsushita T, Tedder TF,. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 2010; 1183: 38-57.
18. Pallier A, Hillion S, Danger R, et al,. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010; 78: 503-513.
19. Newell KA, Asare A, Kirk AD, et al,. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836-1847.
20. Zhao G, Moore DJ, Lee KM, et al,. An unexpected counter-regulatory role of IL-10 in B-lymphocyte-mediated transplantation tolerance. Am J Transplant 2010; 10: 796-801.
21. Kirk AD, Turgeon NA, Iwakoshi NN,. B cells and transplantation tolerance. Nat Rev Nephrol 2010; 6: 584-593.
22. Ostergaard M, Baslund B, Rigby W, et al,. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 2010; 62: 2227-2238.
23. Tedder TF,. CD19: A promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 572-577.
24. Dilillo DJ, Griffiths R, Seshan SV, et al,. B lymphocytes differentially influence acute and chronic allograft rejection in mice. J Immunol 2011; 186: 2643-2654.
25. Zarkhin V, Chalasani G, Sarwal MM,. The yin and yang of B cells in graft rejection and tolerance. Transplant Rev 2010; 24: 67-78.
26. Fehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP, Gaspert A,. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009; 87: 1837-1841.
27. Vo AA, Peng A, Toyoda M, et al,. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095-1102.
28. Loupy A, Suberbielle-Boissel C, Zuber J, et al,. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: A pilot study. Transplantation 2010; 89: 1403-1410.
29. Kayler LK, Lakkis FG, Morgan C, et al,. Acute cellular rejection with CD20-positive lymphoid clusters in kidney transplant patients following lymphocyte depletion. Am J Transplant 2007; 7: 949-954. (Pubitemid 46481212)
30. Tyden G, Genberg H, Tollemar J, et al,. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325-1329.
31. Clatworthy MR, Watson CJ, Plotnek G, et al,. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360: 2683-2685.
32. Kim MJ, Kim HO, Kim HY, Park YM,. Rituximab-induced vasculitis: A case report and review of the medical published work. J Dermatol 2009; 36: 284-287.
33. Liu C, Noorchashm H, Sutter JA, et al,. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med 2007; 13: 1295-1298. (Pubitemid 350073600)
34. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR,. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8: R74.
35. Lateef A, Petri M,. Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 2010; 22: 504-509.
36. Zand MS, Vo T, Huggins J, et al,. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79: 1507-1515. (Pubitemid 40847581)
37. Bachler K, Amico P, Honger G, et al,. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 2010; 10: 1254-1262.
38. Everly JJ, Walsh RC, Alloway RR, Woodle ES,. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009; 14: 662-666.
39. Wahrmann M, Haidinger M, Kormoczi GF, et al,. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010; 89: 1385-1390.
40. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al,. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681-686.
41. Trivedi HL, Terasaki PI, Feroz A, et al,. Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients. Transplantation 2010; 90: 221-222.
42. Walsh RC, Everly JJ, Brailey P, et al,. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277-284.
43. Flechner SM, Fatica R, Askar M, et al,. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010; 90: 1486-1492.
44. Ashton-Chess J, Mai HL, Jovanovic V, et al,. Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection. Kidney Int 2010; 77: 880-890.
45. Vogelbacher R, Meister S, Guckel E, et al,. Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat. Nephrol Dial Transplant 2010; 25: 3764-3773.
46. Everly MJ, Terasaki PI, Hopfield J, Trivedi HL, Kaneku H,. Protective immunity remains intact after antibody removal by means of proteasome inhibition. Transplantation 2010; 90: 1483-1488.
47. Zhou P, Comenzo RL, Olshen AB, et al,. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood 2008; 111: 3403-3406.
48. Xiang Z, Cutler AJ, Brownlie RJ, et al,. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol 2007; 8: 419-429. (Pubitemid 46745417)
49. Shehata N, Palda VA, Meyer RM, et al,. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: An evidence-based practice guideline. Transfus Med Rev 2010; 24 Suppl 1: S7-S27.
50. Nimmerjahn F, Ravetch JV,. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513-533. (Pubitemid 351600384)
51. Tha-In T, Metselaar HJ, Bushell AR, Kwekkeboom J, Wood KJ,. Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4+Foxp3+ T cells. Transplantation 2010; 89: 1446-1455.
52. Locke JE, Magro CM, Singer AL, et al,. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231-235.
53. Lonze BE, Dagher NN, Simpkins CE, et al,. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant 2010; 10: 2154-2160.
54. Stegall MD, Diwan TS, Burns JM,. Prevention of acute humoral rejection with C5 inhibition. [2009 ATC abstract 178]. Am J Transplant 2009; 9 (suppl 2): 241-242.